In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Series B brings in $45.5mm for Akero

Executive Summary

Akero Therapeutics Inc. raised $45.5mm through a Series B round led by Janus Henderson Investors, which was joined by other first-time backers Redmile Group, Boxer Capital of Tavistock Group, Cormorant Asset Management, BVF Partners, Rock Springs Capital, and LifeSci Venture Partners, and returning shareholders Apple Tree Partners, Atlas Venture, venBio Partners, and Versant Ventures. According to the Form D filing, 20 investors participated. The company will use the proceeds to move its lead program AKR001 (licensed from Amgen in June) through Phase II trials for nonalcoholic steatohepatitis, to scale manufacturing, and expand its metabolic disease pipeline.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies

UsernamePublicRestriction

Register